That’s not my title! I owe thanks to blogger AnneMarie Ciccarella for that title. You might imagine my thoughts reading it. It blew me away! It was gratifying and exciting, and it’s not just that one title – that’s how it’s been all month with reporters, bloggers, and users as they get exposed to Medivizor and share their thoughts. AnneMarie was among several bloggers (we love you all!) whom have written about us and encouraged their readers to try Medivizor out. As a result, many users requested and received invitations to our early access, signed up, and began using Medivizor.
Continuing the annual tradition: Last year, my predictions for 2012 turned out to be remarkably good with 85% accuracy! That’s even better than the 77% accuracy of 2010 and 2011 predictions. If you want to check it out yourself, here’s the scorecard.
I loved the video summary Google did for 2012. I actually didn’t mention many of these developments. So surely you must consider my predictions not “all that will be”, but rather, what will be within specific areas that I’m focused on. Obviously, there’s a lot more going on that I don’t touch on.
A recent study by researchers at Loyola University found that as many as 63% of prostate cancer websites cannot be read or understood by someone who hasn’t completed high school education. Why is this important? Well, one of the study’s references suggests that as many as 90 million adult Americans have literacy skills that test below high school reading levels. This is despite the fact that 87.58% of US adults over 25 years old have a high school education (US Census Data). Also, people with lower socioeconomic backgrounds may have even lower reading levels (as much as 7th-8th grade, on average). In fact, The National Institute of Health (NIH) recommends that providers prepare patient education material suited to fit 4th through 6th grade reading level.
It’s been awhile since my last blog post. I apologize, I’ve been busy. I’ve spent most of my time helping several startups get off the ground, some of which you’ll hear more about very soon. Among these, and the one I’ve spent the bulk of my energy on, is Medivizor. Over the next few weeks and months I’ll be sharing in this blog about the challenges that Medivizor is addressing, the challenges of starting a new company, and some of our experiences.